

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



(10) International Publication Number

WO 2016/144635 A1

(43) International Publication Date  
15 September 2016 (15.09.2016)

WIPO | PCT

(51) International Patent Classification:  
*A61K 31/496* (2006.01)    *A61P 35/00* (2006.01)

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(21) International Application Number:  
PCT/US2016/020390

(22) International Filing Date:  
2 March 2016 (02.03.2016)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
62/129,654            6 March 2015 (06.03.2015)    US  
62/249,788            2 November 2015 (02.11.2015)    US

(71) Applicant: BEYONDSPRING PHARMACEUTICALS, INC. [US/US]; 28 Liberty Street 39th Floor, New York, NY 10005 (US).

(72) Inventor: HUANG, Lan; 28 Liberty Street 39th Floor, New York, NY 10005 (US).

(74) Agent: MALLON, Joseph, J.; Knobbe, Martens, Olson & Bear, LLP, 2040 Main Street, 14th Floor, Irvine, CA 92614 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

**Published:**

- with international search report (Art. 21(3))



WO 2016/144635 A1

(54) Title: METHOD OF TREATING CANCER ASSOCIATED WITH A RAS MUTATION

(57) Abstract: Disclosed herein are methods of treating a cancer characterized by expressing a mutant form of a RAS protein. Some embodiments relate to treatment of cancer by administering Plinabulin to a subject in need thereof.

**METHOD OF TREATING CANCER ASSOCIATED WITH A RAS MUTATION****INCORPORATION BY REFERENCE TO ANY PRIORITY APPLICATIONS**

**[0001]** This application claims the benefit of U.S. Provisional Application No. 62/129654, filed March 6, 2015, and U.S. Provisional Application No. 62/249788, filed November 2, 2015, the disclosure of which are incorporated herein by reference in their entireties.

**BACKGROUND****Field**

**[0002]** The present invention relates to the field of chemistry and medicine. More particularly, the present invention relates to method of treating cancer associated with a RAS mutation using Plinabulin.

**Description of the Related Art**

**[0003]** RAS proteins function as binary molecular switches that control intracellular signaling networks. RAS-regulated signal pathways control processes such as actin cytoskeletal integrity, proliferation, differentiation, cell adhesion, apoptosis, and cell migration. The RAS subfamily includes at least 21 members such as KRAS, NRAS, and HRAS. RAS or RAS-related protein relay signals from outside the cell to the cell's nucleus. These signals instruct the cell to grow and divide or to mature and take on specialized functions (differentiate). The RAS proteins belong to a class of protein called GTPase, which means it converts a molecule called GTP into another molecule called GDP. A RAS protein acts like a switch, and it is turned on and off by the GTP and GDP molecules. To transmit signals, the RAS protein must be turned on by attaching (binding) to a molecule of GTP. A RAS protein is turned off (inactivated) when it converts the GTP to GDP. When the protein is bound to GDP, it does not relay signals to the cell's nucleus. When a RAS protein is mutated at certain codons, the RAS protein is stuck in its GTP bound state, so it keeps sending signal to nucleus and the cell could not stop dividing, which is un-controlled cell growth or cancer.

**[0004]** The *RAS* genes belong to a class of genes known as oncogenes. A mutant form of RAS gene has the potential to cause normal cells to become cancerous. The proteins produced from these *RAS* genes are GTPases. These proteins play important roles in cell division, cell differentiation, and the cell apoptosis. However, the

mechanisms by which oncogenic RAS coordinates the shift in metabolism to sustain tumor growth, particularly in the tumor microenvironment, and whether specific metabolic pathways are essential for RAS-mediated tumor maintenance remain areas of active investigation. Cancers characterized by a RAS mutation are difficult to treat using known therapies, and there are no approved drugs for treating these cancers. RAS mutation is a negative predictor of cancer patient survival; cancer patients have much poorer prognostic outcome (or shorter overall survival) when their cancer has RAS mutation. Thus, there is a dire unmet need for a more effective treatment for cancer associated with oncogenic RAS gene mutation.

## SUMMARY

**[0005]** Some embodiments relate to a method of treating a cancer characterized by expressing a mutant form of RAS protein, comprising administering Plinabulin to a subject in need thereof.

**[0006]** Some embodiments relate to a method of treating a cancer characterized by expressing a mutant form of KRAS protein, comprising administering Plinabulin to a subject in need thereof.

**[0007]** Some embodiments relate to a method of treating a cancer characterized by expressing a mutant form of NRAS protein, comprising administering Plinabulin to a subject in need thereof.

**[0008]** Some embodiments relate to a method of inhibiting proliferation of a cell having a RAS mutation, comprising contacting the cell with Plinabulin.

**[0009]** Some embodiments relate to a method of inducing apoptosis in a cell having a RAS mutation, comprising contacting the cell with Plinabulin.

**[0010]** Some embodiments relate to a method of inhibiting progression of a cancer characterized by expressing a mutant form of RAS protein in a subject, comprising administering Plinabulin to a subject in need thereof.

## BRIEF DESCRIPTION OF THE DRAWINGS

**[0011]** FIGS 1a-1d show the proneural genetically engineered murine model (GEMM) of glioblastoma (GBM) that mimics human pathology. FIG. 1a shows T2 MRI images of a human GBM that display peritumoral edema; and FIG. 1b shows T2 MRI images of mouse GBM that display peritumoral edema; FIG 1c shows human micrograph images of H&E stains of a GBM showing hallmark pseudopalisading necrosis and

microvascular proliferation; FIG. 1d shows mouse micrograph images of H&E stains of a GBM showing hallmark pseudopalisading necrosis and microvascular proliferation.

**[0012]** FIG 2 shows tumor size of mice with PDGF-induced gliomas treated with vehicle, temozolomide or fractionated radiation.

**[0013]** FIG. 3 shows the tumor weight autopsy in mice treated with vehicle only, Docetaxel only, and a combination of Plinabulin and Docetaxel.

**[0014]** FIG. 4 shows the survival rate of mice with PDGF-induced gliomas characterized by expression of KRAS mutation that were treated with control and Plinabulin.

**[0015]** FIG. 5 shows the survival rate of mice with PDGF-induced gliomas characterized by expression of KRAS mutation that were treated with the combination of plinabulin, temozolomide, and radiation and the combination of temozolomide and radiation.

**[0016]** FIG. 6 shows the change in tumor volume in mice with the HCT-15 (Kras mutation G13D) human colon tumor xenograft throughout the course of the study in mice treated with vehicle control, plinabulin, irinotecan, or the combination of plinabulin and irinotecan.

**[0017]** FIG. 7 shows the change in tumor volume in mice with the Lovo (Kras mutation, p.G13D) human colon tumor xenograft throughout the course of the study in mice treated with vehicle control, plinabulin, irinotecan, or the combination of plinabulin and irinotecan.

#### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

**[0018]** Plinabulin, (3Z,6Z)-3-Benzylidene-6-{[5-(2-methyl-2-propanyl)-1*H*-imidazol-4-yl]methylene}-2,5-piperazinedione, is a synthetic analog of the natural compound phenylahistin. Plinabulin can be readily prepared according to methods and procedures detailed in U.S. Patents 7,064,201 and 7,919,497, which are incorporated herein by reference in their entireties. Some embodiments relate to the use of Plinabulin to treat cancer associated with an oncogenic RAS mutation. Some embodiments relate to the use of Plinabulin to treat a cancer characterized by expressing a mutant form of RAS protein in a subject. Some embodiments relate to the use of Plinabulin to inhibit proliferation of a cell having a RAS mutation. Some embodiments relate to the use of Plinabulin to induce apoptosis in a cell having a RAS mutation. Some embodiments relate to the use of Plinabulin to inhibit progression of a cancer that is characterized by

expressing a mutant form of RAS protein in a subject. In some embodiments, the RAS protein is a KRAS protein. In some embodiments, the RAS protein is a NRAS protein.

Definitions

**[0019]** Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art to which this disclosure belongs. All patents, applications, published applications, and other publications are incorporated by reference in their entirety. In the event that there is a plurality of definitions for a term herein, those in this section prevail unless stated otherwise.

**[0020]** “Subject” as used herein, means a human or a non-human mammal, e.g., a dog, a cat, a mouse, a rat, a cow, a sheep, a pig, a goat, a non-human primate or a bird, e.g., a chicken, as well as any other vertebrate or invertebrate.

**[0021]** The term “mammal” is used in its usual biological sense. Thus, it specifically includes, but is not limited to, primates, including simians (chimpanzees, apes, monkeys) and humans, cattle, horses, sheep, goats, swine, rabbits, dogs, cats, rodents, rats, mice guinea pigs, or the like.

**[0022]** An “effective amount” or a “therapeutically effective amount” as used herein refers to an amount of a therapeutic agent that is effective to relieve, to some extent, or to reduce the likelihood of onset of, one or more of the symptoms of a disease or condition, and includes curing a disease or condition.

**[0023]** “Treat,” “treatment,” or “treating,” as used herein refers to administering a compound or pharmaceutical composition to a subject for prophylactic and/or therapeutic purposes. The term “prophylactic treatment” refers to treating a subject who does not yet exhibit symptoms of a disease or condition, but who is susceptible to, or otherwise at risk of, a particular disease or condition, whereby the treatment reduces the likelihood that the patient will develop the disease or condition. The term “therapeutic treatment” refers to administering treatment to a subject already suffering from a disease or condition.

**[0024]** The term “pharmaceutically acceptable salt” refers to salts that retain the biological effectiveness and properties of a compound and, which are not biologically or otherwise undesirable for use in a pharmaceutical. In many cases, the compounds disclosed herein are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto. Pharmaceutically acceptable acid

addition salts can be formed with inorganic acids and organic acids. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. Pharmaceutically acceptable salts can also be formed using inorganic and organic bases. Inorganic bases from which salts can be derived include, for example, bases that contain sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like; particularly preferred are the ammonium, potassium, sodium, calcium and magnesium salts. In some embodiments, treatment of the compounds disclosed herein with an inorganic base results in loss of a labile hydrogen from the compound to afford the salt form including an inorganic cation such as  $\text{Li}^+$ ,  $\text{Na}^+$ ,  $\text{K}^+$ ,  $\text{Mg}^{2+}$  and  $\text{Ca}^{2+}$  and the like. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like, specifically such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine. Many such salts are known in the art, as described in WO 87/05297, Johnston et al., published September 11, 1987 (incorporated by reference herein in its entirety).

**[0025]** In some embodiments, the composition can further include one or more pharmaceutically acceptable diluents. In some embodiments, the pharmaceutically acceptable diluent can include kolliphor® (Polyethylene glycol (15)-hydroxystearate). In some embodiments, the pharmaceutically acceptable diluent can include propylene glycol. In some embodiments, the pharmaceutically acceptable diluents can include kolliphor and propylene glycol. In some embodiments, the pharmaceutically acceptable diluents can include kolliphor and propylene glycol, wherein the kolliphor is about 40% by weight and propylene glycol is about 60% by weight based on the total weight of the diluents. In some embodiments, the composition can further include one or more other pharmaceutically acceptable excipients.

**[0026]** Standard pharmaceutical formulation techniques can be used to make the pharmaceutical compositions described herein, such as those disclosed in Remington's

The Science and Practice of Pharmacy, 21st Ed., Lippincott Williams & Wilkins (2005), incorporated herein by reference in its entirety. Accordingly, some embodiments include pharmaceutical compositions comprising: (a) a safe and therapeutically effective amount of Plinabulin or pharmaceutically acceptable salts thereof; and (b) a pharmaceutically acceptable carrier, diluent, excipient or combination thereof.

**[0027]** Other embodiments include co-administering Plinabulin and an additional therapeutic agent in separate compositions or the same composition. Thus, some embodiments include a first pharmaceutical composition comprising: (a) a safe and therapeutically effective amount of Plinabulin or pharmaceutically acceptable salts thereof and (b) a pharmaceutically acceptable carrier, diluent, excipient or combination thereof; and a second pharmaceutical composition comprising: (a) a safe and therapeutically effective amount of an additional therapeutic agent and (b) a pharmaceutically acceptable carrier, diluent, excipient or combination thereof. Some embodiments include a pharmaceutical composition comprising: (a) a safe and therapeutically effective amount of Plinabulin or pharmaceutically acceptable salts thereof; (b) a safe and therapeutically effective amount of an additional therapeutic agent; and (c) a pharmaceutically acceptable carrier, diluent, excipient or combination thereof.

**[0028]** Administration of the pharmaceutical compositions described herein can be via any of the accepted modes of administration for agents that serve similar utilities including, but not limited to, orally, sublingually, buccally, subcutaneously, intravenously, intranasally, topically, transdermally, intradermally, intraperitoneally, intramuscularly, intrapulmonarily, vaginally, rectally, or intraocularly. Oral and parenteral administrations are customary in treating the indications that are the subject of the preferred embodiments.

**[0029]** The term “pharmaceutically acceptable carrier” or “pharmaceutically acceptable excipient” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. In addition, various adjuvants such as are commonly used in the art may be included. Considerations for the inclusion of various components in pharmaceutical compositions are described, e.g., in Gilman et al. (Eds.) (1990); Goodman and Gilman’s: The Pharmacological Basis of

Therapeutics, 8th Ed., Pergamon Press, which is incorporated herein by reference in its entirety.

**[0030]** Some examples of substances, which can serve as pharmaceutically-acceptable carriers or components thereof, are sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, and methyl cellulose; powdered tragacanth; malt; gelatin; talc; solid lubricants, such as stearic acid and magnesium stearate; calcium sulfate; vegetable oils, such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil and oil of theobroma; polyols such as propylene glycol, glycerin, sorbitol, mannitol, and polyethylene glycol; alginic acid; emulsifiers, such as the TWEENS; wetting agents, such sodium lauryl sulfate; coloring agents; flavoring agents; tableting agents, stabilizers; antioxidants; preservatives; pyrogen-free water; isotonic saline; and phosphate buffer solutions.

**[0031]** The compositions described herein are preferably provided in unit dosage form. As used herein, a "unit dosage form" is a composition containing an amount of a compound or composition that is suitable for administration to an animal, preferably a mammalian subject, in a single dose, according to good medical practice. The preparation of a single or unit dosage form however, does not imply that the dosage form is administered once per day or once per course of therapy. Such dosage forms are contemplated to be administered once, twice, thrice or more per day and may be administered as infusion over a period of time (e.g., from about 30 minutes to about 2-6 hours), or administered as a continuous infusion, and may be given more than once during a course of therapy, although a single administration is not specifically excluded. The skilled artisan will recognize that the formulation does not specifically contemplate the entire course of therapy and such decisions are left for those skilled in the art of treatment rather than formulation.

**[0032]** The compositions useful as described above may be in any of a variety of suitable forms for a variety of routes for administration, for example, for oral, sublingual, buccal, nasal, rectal, topical (including transdermal and intradermal), ocular, intracerebral, intracranial, intrathecal, intra-arterial, intravenous, intramuscular, or other parenteral routes of administration. The skilled artisan will appreciate that oral and nasal compositions include compositions that are administered by inhalation, and made using available methodologies. Depending upon the particular route of administration desired,

a variety of pharmaceutically-acceptable carriers well-known in the art may be used. Pharmaceutically-acceptable carriers include, for example, solid or liquid fillers, diluents, hydrotropies, surface-active agents, and encapsulating substances. Optional pharmaceutically-active materials may be included, which do not substantially interfere with the activity of the compound or composition. The amount of carrier employed in conjunction with the compound or composition is sufficient to provide a practical quantity of material for administration per unit dose of the compound. Techniques and compositions for making dosage forms useful in the methods described herein are described in the following references, all incorporated by reference herein: Modern Pharmaceutics, 4th Ed., Chapters 9 and 10 (Banker & Rhodes, editors, 2002); Lieberman *et al.*, Pharmaceutical Dosage Forms: Tablets (1989); and Ansel, Introduction to Pharmaceutical Dosage Forms 8th Edition (2004).

**[0033]** Various oral dosage forms can be used, including such solid forms as tablets, capsules (e.g., liquid gel capsule and solid gel capsule), granules and bulk powders. Tablets can be compressed, tablet triturates, enteric-coated, sugar-coated, film-coated, or multiple-compressed, containing suitable binders, lubricants, diluents, disintegrating agents, coloring agents, flavoring agents, flow-inducing agents, and melting agents. Liquid oral dosage forms include aqueous solutions, emulsions, suspensions, solutions and/or suspensions reconstituted from non-effervescent granules, and effervescent preparations reconstituted from effervescent granules, containing suitable solvents, preservatives, emulsifying agents, suspending agents, diluents, sweeteners, melting agents, coloring agents and flavoring agents.

**[0034]** The pharmaceutically-acceptable carriers suitable for the preparation of unit dosage forms for peroral administration is well-known in the art. Tablets typically comprise conventional pharmaceutically-compatible adjuvants as inert diluents, such as calcium carbonate, sodium carbonate, mannitol, lactose and cellulose; binders such as starch, gelatin and sucrose; disintegrants such as starch, alginic acid and croscarmelose; lubricants such as magnesium stearate, stearic acid and talc. Glidants such as silicon dioxide can be used to improve flow characteristics of the powder mixture. Coloring agents, such as the FD&C dyes, can be added for appearance. Sweeteners and flavoring agents, such as aspartame, saccharin, menthol, peppermint, and fruit flavors, are useful adjuvants for chewable tablets. Capsules typically comprise one or more solid diluents disclosed above. The selection of carrier components depends on secondary

considerations like taste, cost, and shelf stability, which are not critical, and can be readily made by a person skilled in the art.

**[0035]** Peroral compositions also include liquid solutions, emulsions, suspensions, and the like. The pharmaceutically-acceptable carriers suitable for preparation of such compositions are well known in the art. Typical components of carriers for syrups, elixirs, emulsions and suspensions include ethanol, glycerol, propylene glycol, polyethylene glycol, liquid sucrose, sorbitol and water. For a suspension, typical suspending agents include methyl cellulose, sodium carboxymethyl cellulose, AVICEL RC-591, tragacanth and sodium alginate; typical wetting agents include lecithin and polysorbate 80; and typical preservatives include methyl paraben and sodium benzoate. Peroral liquid compositions may also contain one or more components such as sweeteners, flavoring agents and colorants disclosed above.

**[0036]** Such compositions may also be coated by conventional methods, typically with pH or time-dependent coatings, such that the subject composition is released in the gastrointestinal tract in the vicinity of the desired topical application, or at various times to extend the desired action. Such dosage forms typically include, but are not limited to, one or more of cellulose acetate phthalate, polyvinylacetate phthalate, hydroxypropyl methyl cellulose phthalate, ethyl cellulose, Eudragit coatings, waxes and shellac.

**[0037]** Compositions described herein may optionally include other drug actives.

**[0038]** Other compositions useful for attaining systemic delivery of the subject compounds include sublingual, buccal and nasal dosage forms. Such compositions typically comprise one or more of soluble filler substances such as sucrose, sorbitol and mannitol; and binders such as acacia, microcrystalline cellulose, carboxymethyl cellulose and hydroxypropyl methyl cellulose. Glidants, lubricants, sweeteners, colorants, antioxidants and flavoring agents disclosed above may also be included.

**[0039]** A liquid composition, which is formulated for topical ophthalmic use, is formulated such that it can be administered topically to the eye. The comfort may be maximized as much as possible, although sometimes formulation considerations (e.g. drug stability) may necessitate less than optimal comfort. In the case that comfort cannot be maximized, the liquid may be formulated such that the liquid is tolerable to the patient for topical ophthalmic use. Additionally, an ophthalmically acceptable liquid may either

be packaged for single use, or contain a preservative to prevent contamination over multiple uses.

**[0040]** For ophthalmic application, solutions or medicaments are often prepared using a physiological saline solution as a major vehicle. Ophthalmic solutions may preferably be maintained at a comfortable pH with an appropriate buffer system. The formulations may also contain conventional, pharmaceutically acceptable preservatives, stabilizers and surfactants.

**[0041]** Preservatives that may be used in the pharmaceutical compositions disclosed herein include, but are not limited to, benzalkonium chloride, PHMB, chlorobutanol, thimerosal, phenylmercuric, acetate and phenylmercuric nitrate. A useful surfactant is, for example, Tween 80. Likewise, various useful vehicles may be used in the ophthalmic preparations disclosed herein. These vehicles include, but are not limited to, polyvinyl alcohol, povidone, hydroxypropyl methyl cellulose, poloxamers, carboxymethyl cellulose, hydroxyethyl cellulose and purified water.

**[0042]** Tonicity adjustors may be added as needed or convenient. They include, but are not limited to, salts, particularly sodium chloride, potassium chloride, mannitol and glycerin, or any other suitable ophthalmically acceptable tonicity adjustor.

**[0043]** Various buffers and means for adjusting pH may be used so long as the resulting preparation is ophthalmically acceptable. For many compositions, the pH will be between 4 and 9. Accordingly, buffers include acetate buffers, citrate buffers, phosphate buffers and borate buffers. Acids or bases may be used to adjust the pH of these formulations as needed.

**[0044]** Ophthalmically acceptable antioxidants include, but are not limited to, sodium metabisulfite, sodium thiosulfate, acetylcysteine, butylated hydroxyanisole and butylated hydroxytoluene.

**[0045]** Other excipient components, which may be included in the ophthalmic preparations, are chelating agents. A useful chelating agent is edetate disodium (EDTA), although other chelating agents may also be used in place or in conjunction with it.

**[0046]** For topical use, creams, ointments, gels, solutions or suspensions, etc., containing the composition disclosed herein are employed. Topical formulations may generally be comprised of a pharmaceutical carrier, co-solvent, emulsifier, penetration enhancer, preservative system, and emollient.

**[0047]** For intravenous administration, the compositions described herein may be dissolved or dispersed in a pharmaceutically acceptable diluent, such as a saline or dextrose solution. Suitable excipients may be included to achieve the desired pH, including but not limited to NaOH, sodium carbonate, sodium acetate, HCl, and citric acid. In various embodiments, the pH of the final composition ranges from 2 to 8, or preferably from 4 to 7. Antioxidant excipients may include sodium bisulfite, acetone sodium bisulfite, sodium formaldehyde, sulfoxylate, thiourea, and EDTA. Other non-limiting examples of suitable excipients found in the final intravenous composition may include sodium or potassium phosphates, citric acid, tartaric acid, gelatin, and carbohydrates such as dextrose, mannitol, and dextran. Further acceptable excipients are described in Powell, et al., Compendium of Excipients for Parenteral Formulations, *PDA J Pharm Sci and Tech* **1998**, 52 238-311 and Nema et al., Excipients and Their Role in Approved Injectable Products: Current Usage and Future Directions, *PDA J Pharm Sci and Tech* **2011**, 65 287-332, both of which are incorporated herein by reference in their entirety. Antimicrobial agents may also be included to achieve a bacteriostatic or fungistatic solution, including but not limited to phenylmercuric nitrate, thimerosal, benzethonium chloride, benzalkonium chloride, phenol, cresol, and chlorobutanol.

**[0048]** The compositions for intravenous administration may be provided to caregivers in the form of one or more solids that are reconstituted with a suitable diluent such as sterile water, saline or dextrose in water shortly prior to administration. In other embodiments, the compositions are provided in solution ready to administer parenterally. In still other embodiments, the compositions are provided in a solution that is further diluted prior to administration. In embodiments that include administering a combination of a compound described herein and another agent, the combination may be provided to caregivers as a mixture, or the caregivers may mix the two agents prior to administration, or the two agents may be administered separately.

**[0049]** The actual dose of the active compounds described herein depends on the specific compound, and on the condition to be treated; the selection of the appropriate dose is well within the knowledge of the skilled artisan. In some embodiments, a single dose of Plinabulin or other therapeutic agent may be from about 5 mg/m<sup>2</sup> to about 150 mg/m<sup>2</sup> of body surface area, from about 5 mg/m<sup>2</sup> to about 100 mg/m<sup>2</sup> of body surface area, from about 10 mg/m<sup>2</sup> to about 100 mg/m<sup>2</sup> of body surface area, from about 10 mg/m<sup>2</sup> to about 80 mg/m<sup>2</sup> of body surface area, from about 10 mg/m<sup>2</sup> to about 50 mg/m<sup>2</sup>

of body surface area, from about 10 mg/m<sup>2</sup> to about 40 mg/m<sup>2</sup> of body surface area, from about 10 mg/m<sup>2</sup> to about 30 mg/m<sup>2</sup> of body surface area, from about 13.5 mg/m<sup>2</sup> to about 100 mg/m<sup>2</sup> of body surface area, from about 13.5 mg/m<sup>2</sup> to about 80 mg/m<sup>2</sup> of body surface area, from about 13.5 mg/m<sup>2</sup> to about 50 mg/m<sup>2</sup> of body surface area, from about 13.5 mg/m<sup>2</sup> to about 40 mg/m<sup>2</sup> of body surface area, from about 13.5 mg/m<sup>2</sup> to about 30 mg/m<sup>2</sup> of body surface area, from about 15 mg/m<sup>2</sup> to about 80 mg/m<sup>2</sup> of body surface area, from about 15 mg/m<sup>2</sup> to about 50 mg/m<sup>2</sup> of body surface area, or from about 15 mg/m<sup>2</sup> to about 30 mg/m<sup>2</sup> of body surface area. In some embodiments, a single dose of Plinabulin or other therapeutic agent may be from about 13.5 mg/m<sup>2</sup> to about 30 mg/m<sup>2</sup> of body surface area. In some embodiments, a single dose of Plinabulin or other therapeutic agent may be about 5 mg/m<sup>2</sup>, about 10 mg/m<sup>2</sup>, about 12.5 mg/m<sup>2</sup>, about 13.5 mg/m<sup>2</sup>, about 15 mg/m<sup>2</sup>, about 17.5 mg/m<sup>2</sup>, about 20 mg/m<sup>2</sup>, about 22.5 mg/m<sup>2</sup>, about 25 mg/m<sup>2</sup>, about 27.5 mg/m<sup>2</sup>, about 30 mg/m<sup>2</sup>, about 40 mg/m<sup>2</sup>, about 50 mg/m<sup>2</sup>, about 60 mg/m<sup>2</sup>, about 70 mg/m<sup>2</sup>, about 80 mg/m<sup>2</sup>, about 90 mg/m<sup>2</sup>, or about 100 mg/m<sup>2</sup>, of body surface area.

**[0050]** In some embodiments, a single dose of Plinabulin or other therapeutic agent may be from about 5 mg to about 300 mg, from about 5 mg to about 200 mg, from about 7.5 mg to about 200 mg, from about 10 mg to about 100 mg, from about 15 mg to about 100 mg, from about 20 mg to about 100 mg, from about 30 mg to about 100 mg, from about 40 mg to about 100 mg, from about 10 mg to about 80 mg, from about 15 mg to about 80 mg, from about 20 mg to about 80 mg, from about 30 mg to about 80 mg, from about 40 mg to about 80 mg, from about 10 mg to about 60 mg, from about 15 mg to about 60 mg, from about 20 mg to about 60 mg, from about 30 mg to about 60 mg, or from about 40 mg to about 60 mg. In some embodiments, a single dose of Plinabulin or other therapeutic agent may be from about 20 mg to about 60 mg, from about 27 mg to about 60 mg, from about 20 mg to about 45 mg, or from about 27 mg to about 45 mg. In some embodiments, a single dose of Plinabulin or other therapeutic agent may be about 5 mg, about 10 mg, about 12.5 mg, about 13.5 mg, about 15 mg, about 17.5 mg, about 20 mg, about 22.5 mg, about 25 mg, about 27 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 125 mg, about 150 mg, or about 200 mg.

**[0051]** The administration period can be a multi-week treatment cycle as long as the tumor remains under control and the regimen is clinically tolerated. In some

embodiments, a single dosage of Plinabulin or other therapeutic agent can be administered once a week, and preferably once on each of day 1 and day 8 of a three-week (21 day) treatment cycle. In some embodiments, a single dosage of Plinabulin or other therapeutic agent can be administered once a week, twice a week, three times per week, four times per week, five times per week, six times per week, or daily during a one-week, two-week, three-week, four-week, or five-week treatment cycle. The administration can be on the same or different day of each week in the treatment cycle.

**[0052]** The treatment cycle can be repeated as long as the regimen is clinically tolerated. In some embodiments, the treatment cycle is repeated for n times, wherein n is an integer in the range of 2 to 30. In some embodiments, n is 2, 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, a new treatment cycle can occur immediately after the completion of the previous treatment cycle. In some embodiments, a new treatment cycle can occur a period of time after the completion of the previous treatment cycle.

**[0053]** In some embodiments, the compositions described herein can be used in combination with other therapeutic agents. In some embodiments, the compositions described herein can be administered or used in combination with treatments such as chemotherapy, radiation, and biologic therapies.

#### Methods of Treatment

**[0054]** Some embodiments relate to a method of treating a cancer characterized by expressing a mutant form of a RAS protein, comprising administering Plinabulin to a subject in need thereof. Some embodiments relate to a method of treating a cancer associated with an oncogenic RAS mutation, comprising administering Plinabulin to a subject in need thereof.

**[0055]** In some embodiments, the mutant form of the RAS protein is a mutant form of a KRAS, NRAS, or HRAS protein. In some embodiments, the RAS protein is a KRAS, NRAS, or HRAS protein. In some embodiments, the mutant form of the RAS is a mutant form of the KRAS protein. In some embodiments, the mutant form of the RAS is a mutant form of the NRAS protein. In some embodiments, the RAS gene mutation is KRAS gene mutation. In some embodiments, the RAS gene mutation is NRAS gene mutation.

**[0056]** Some embodiments relate to a method of treating a cancer characterized by expressing a mutant form of a KRAS protein, comprising administering

Plinabulin to a subject in need thereof. Some embodiments relate to a method of treating a cancer associated with an oncogenic KRAS mutation, comprising administering Plinabulin to a subject in need thereof.

**[0057]** Some embodiments relate to a method of treating a cancer characterized by expressing a mutant form of a NRAS protein, comprising administering Plinabulin to a subject in need thereof. Some embodiments relate to a method of treating a cancer associated with an oncogenic NRAS mutation, comprising administering Plinabulin to a subject in need thereof.

**[0058]** Some embodiments of the present invention include methods of treating cancer with Plinabulin and compositions comprising Plinabulin described herein. Some methods include administering a compound, composition, pharmaceutical composition described herein to a subject in need thereof. In some embodiments, a subject can be an animal, e.g., a mammal, a human.

**[0059]** In some embodiments, cancer is selected from colorectal cancer, pancreatic cancer, renal cancer, lung cancer, liver cancer, breast cancer, prostate cancer, gastrointestinal cancer, peritoneal cancer, melanoma, endometrial cancer, ovarian cancer, cervical cancer, uterine carcinoma, bladder cancer, glioblastoma, brain metastases, salivary gland carcinoma, thyroid cancer, brain cancer, lymphoma, myeloma, and head and neck cancer. In some embodiments, the cancer is selected from squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, squamous carcinoma of the lung, hepatocellular carcinoma, colon cancer, endometrial carcinoma, and hepatocellular carcinoma. In some embodiments, the cancer is selected from colorectal cancer, prostate cancer, breast cancer, lung cancer, endometrial cancer, multiple myeloma, pancreatic, renal cancer, and glioblastoma. In some embodiments, the cancer is selected from non-small cell lung cancer, pancreatic cancer, and glioblastoma. In some embodiments, the cancer is non-small cell lung cancer.

**[0060]** In some embodiments, the KRAS comprises mutation at one or more positions selected from codons 12, 13, 59, and 61. In some embodiments, the mutant form of the KRAS protein has mutation at one or more amino acid positions selected from G12, G13, S17, P34, A59, and Q61. In some embodiments, the mutant form of the KRAS protein has one or more amino acid substitutions selected from the group consisting of G12C, G12S, G12R, G12F, G12L, G12N, G12A, G12D, G12V, G13C, G13S, G13D, G13V, G13P, S17G, P34S, A59E, A59G, A59T, Q61K, Q61L, Q61R, and

Q61H. In some embodiments, the mutant form of the KRAS protein has mutation at one or more amino acid positions selected from G12, G13, A59, Q61, K117 and A146. In some embodiments, the mutant form of the KRAS protein has one or more amino acid substitutions selected from the group consisting of G12C, G12R, G12S, G12A, G12D, G12V, G13C, G13R, G13S, G13A, G13D, G13V, A59E, A59G, A59T, Q61K, Q61L, Q61R, Q61H, K117N, K117R, K117E, A146P, A146T and A146V. In some embodiments, the mutant form of the KRAS protein has mutation at one or more amino acid positions selected from of G12, G13, A59 and Q61. In some embodiments, the mutant form of the KRAS protein has one or more amino acid substitutions selected from the group consisting of G12C, G12R, G12S, G12A, G12D, G12V, G13C, G13R, G13S, G13A, G13D, A59E, A59G, A59T, Q61K, Q61L, Q61R and Q61H. In some embodiments, the mutant form of the KRAS protein has mutation at one or more amino acid positions selected from G12, G13, and D153. In some embodiments, the mutant form of the KRAS protein has one or more amino acid substitutions selected from the group consisting of G12A, G12C, G12D, G12V, G12S, G13D, and D153V. In some embodiments, , the mutant form of the KRAS protein has one or more amino acid substitutions selected from G12C, G12S, and D153V.

**[0061]** In some embodiments, the NRAS comprises mutation at one or more positions selected from codons 12, 13, 59, 61, and 146. In some embodiments, the mutant form of the KRAS protein has mutation at one or more amino acid positions selected from G12, G13, A59, Q61, K117 and A146. In some embodiments, the mutant form of the KRAS protein has one or more amino acid substitutions selected from the group consisting of G12C, G12R, G12S, G12A, G12D, G12V, G13C, G13R, G13S, G13A, G13D, G13V, A59D, A59T, Q61K, Q61L, Q61R, Q61H, K117N, K117R, K117E, A146P, A146T and A146V. In some embodiments, the mutant form of the NRAS protein has mutation at one or more amino acid positions at Q61 or A146. In some embodiments, the mutant form of the NRAS protein has one or more amino acid substitutions selected from Q61K, Q61H, Q61R, Q61L, Q61N, Q61E, Q61P, A146T, A146P, A146V, and any combinations thereof. In some embodiments, the mutant form of the NRAS protein has one or more amino acid substitutions selected from Q61H, Q61R, Q61L, and any combinations thereof.

**[0062]** Some embodiments relate to a method of inhibiting proliferation of a cell having a RAS mutation, comprising administering Plinabulin to a subject in need

thereof. Some embodiments relate to a method of inducing apoptosis in a cell having a RAS mutation, comprising contacting the cell with Plinabulin. In some embodiments, the contacting includes administering Plinabulin to a subject in need thereof. Some embodiments relate to a method of inhibiting progression of a cancer characterized by expressing a mutant form of RAS in a subject, comprising contacting the cell with Plinabulin. In some embodiments, the contacting includes administering Plinabulin to a subject in need thereof.

**[0063]** Some embodiments relate to a method of inhibiting proliferation of a cell having a KRAS mutation, comprising administering Plinabulin to a subject in need thereof. Some embodiments relate to a method of inducing apoptosis in a cell having a KRAS mutation, comprising contacting the cell with Plinabulin. Some embodiments relate to a method of inhibiting progression of a cancer characterized by expressing a mutant form of KRAS in a subject, comprising contacting the cell with Plinabulin.

**[0064]** Some embodiments relate to a method of inhibiting proliferation of a cell having a NRAS mutation, comprising administering Plinabulin to a subject in need thereof. Some embodiments relate to a method of inducing apoptosis in a cell having a NRAS mutation, comprising contacting the cell with Plinabulin. Some embodiments relate to a method of inhibiting progression of a cancer characterized by expressing a mutant form of NRAS in a subject, comprising contacting the cell with Plinabulin.

**[0065]** In some embodiments, the subject is a human.

**[0066]** Further embodiments include administering a combination of compounds to a subject in need thereof. A combination can include a compound, composition, pharmaceutical composition described herein with an additional medicament.

**[0067]** Some embodiments include co-administering a compound, composition, and/or pharmaceutical composition described herein, with an additional medicament. By “co-administration,” it is meant that the two or more agents may be found in the patient’s bloodstream at the same time, regardless of when or how they are actually administered. In one embodiment, the agents are administered simultaneously. In one such embodiment, administration in combination is accomplished by combining the agents in a single dosage form. In another embodiment, the agents are administered sequentially. In one embodiment the agents are administered through the same route,

such as orally. In another embodiment, the agents are administered through different routes, such as one being administered orally and another being administered i.v.

**[0068]** The treatment method described herein can include co-administering Plinabulin with an additional active agent. In some embodiments, the method further includes administering an additional therapeutic agent. In some embodiments, the additional therapeutic agent is docetaxel and the cancer is human non-small cell lung cancer. In some embodiments, the additional therapeutic agent is Bevacizumab and the cancer is human non-small cell lung cancer. In some embodiments, the additional therapeutic agent is Irinotecan and the cancer is colon cancer. In some embodiments, the additional therapeutic agent is Temozolomide and the cancer is glioblastoma. In some embodiments, the additional therapeutic agent is irinotecan and the cancer is colon cancer.

**[0069]** In some embodiments, the additional therapeutic agent can be temozolomide, bevacizumab, everolimus, carmustine, lomustine, procarbazine, vincristine, irinotecan, cisplatin, carboplatin, methotrexate, etoposide, vinblasatine, bleomycin, actinomycin, cyclophosphamide, or ifosfamide. In some embodiments, the additional therapeutic agent is selected from bevacizumab, docetaxel, Irinotecan, and temozolomide. In some embodiments, the additional therapeutic agent is docetaxel. In some embodiments, the additional therapeutic agent is irinotecan. In some embodiments, the additional therapeutic agent is bevacizumab. In some embodiments, the additional therapeutic agent is temozolomide. In some embodiments, the additional therapeutic agent is gemcitabine. In some embodiments, the additional therapeutic agent is carmustine. In some embodiments, the additional therapeutic agent is lomustine.

**[0070]** The treatment method described herein can also be used in combination with a radiation therapy.

**[0071]** The method described herein can further include identifying a patient having a cancer characterized by expressing a mutant type of RAS protein. In some embodiments, identifying a patient can include determining whether the patient has a RAS mutation. Some embodiments relate to a method for treating cancer in a patient identified as having a RAS mutation, the method comprising administering to the patient a pharmaceutically effective amount of Plinabulin, wherein the patient has been identified by (i) collecting a sample from the patient; (ii) isolating DNA from the sample; (iii) amplifying a RAS gene or fragment thereof in the isolated DNA; and (iv) detecting whether there is a mutation in the amplified RAS gene, thereby determining whether the

patient has a cancer characterized by a RAS mutation. Examples of methods for detecting RAS mutation include but are not limited to Amplified Refractory Mutation System (ARMS) PCR, BEAMing assays, digital PCR, and other suitable primers, and probes for sequencing or PCR.

**[0072]** The method described herein can further include identifying a patient having a cancer characterized by expressing a mutant type of KRAS. In some embodiments, identifying a patient can include determining whether the patient has a KRAS mutation. Some embodiments relate to a method for treating cancer in a patient identified as having a KRAS mutation, the method comprising administering to the patient a pharmaceutically effective amount of Plinabulin, wherein the patient has been identified by (i) collecting a sample from the patient; (ii) isolating DNA from the sample; (iii) amplifying a KRAS gene or fragment thereof in the isolated DNA; and (iv) detecting whether there is a mutation in the amplified KRAS gene, thereby determining whether the patient has a cancer characterized by a KRAS mutation.

**[0073]** The method described herein can further include testing for a KRAS mutation. In some embodiments, KRAS mutations, e.g., at codons 12, 13, 59, 61 and/or 146 may be detected from pathology samples taken from the patient. In some embodiments of such testing, DNA is removed from the sample and tested against labeled oligonucleotide probes using PCR to amplify the targeted mutated DNA to permit detection. In some embodiments, commercial testing centers can carry out such tests. In some embodiments, a test kit such as the TheraScreen: K-RAS Mutation kit (DxS Ltd, 48 Grafton Street, Manchester M1 3 9XX, UK) may be used. For example, the TheraScreen kit can detect mutations in codons 12 and 13 of the K-RAS oncogene:

GIy 12 Asp (GGT>GAT) GIy 12 Arg (GG1>CGT)  
GIy 12 Ala (GGT>GCT) GIy 12Cy s (GGT>TGT)  
GIy 12VaI (GGT>GTT) GIy 13 Asp (GGOGAC) Glyl2Ser (GGT>AGT)

**[0074]** The method described herein can further include identifying a patient having a cancer characterized by expressing a mutant type of NRAS protein. In some embodiments, identifying a patient can include determining whether the patient has a NRAS mutation. Some embodiments relate to a method for treating cancer in a patient identified as having a NRAS mutation, the method comprising administering to the patient a pharmaceutically effective amount of Plinabulin, wherein the patient has been identified by (i) collecting a sample from the patient; (ii) isolating DNA from the sample;

(iii) amplifying a NRAS gene or fragment thereof in the isolated DNA; and (iv) detecting whether there is a mutation in the amplified NRAS gene, thereby determining whether the patient has a cancer characterized by a NRAS mutation.

**[0075]** The method described herein can further include testing for a NRAS mutation. In some embodiments, NRAS mutations, e.g., at codons 12, 13, 59, 61 and/or 146, may be detected from pathology samples taken from the patient. In some embodiments of such testing, DNA is removed from the sample and tested against labeled oligonucleotide probes using PCR to amplify the targeted mutated DNA to permit detection. Several commercially available kits (see Dxs Diagnostic Innovations, Applied Biosystems, and Quest diagnostics), primers and probes for sequencing or PCR can be designed based on the codon mutations of NRAS.

**[0076]** The method described herein can further include identifying a patient having a cancer characterized by expressing a mutant type of HRAS protein. In some embodiments, identifying a patient can include determining whether the patient has a HRAS mutation. Some embodiments relate to a method for treating cancer in a patient identified as having a HRAS mutation, the method comprising administering to the patient a pharmaceutically effective amount of Plinabulin, wherein the patient has been identified by (i) collecting a sample from the patient; (ii) isolating DNA from the sample; (iii) amplifying a HRAS gene or fragment thereof in the isolated DNA; and (iv) detecting whether there is a mutation in the amplified HRAS gene, thereby determining whether the patient has a cancer characterized by a HRAS mutation.

**[0077]** To further illustrate this invention, the following examples are included. The examples should not, of course, be construed as specifically limiting the invention. Variations of these examples within the scope of the claims are within the purview of one skilled in the art and are considered to fall within the scope of the invention as described, and claimed herein. The reader will recognize that the skilled artisan, armed with the present disclosure, and skill in the art is able to prepare and use the invention without exhaustive examples.

## EXAMPLES

## Example 1

**[0078]** All cell lines were grown in their respective proper growth media supplemented with 2-10% FBS and were housed in an atmosphere of 5% CO<sub>2</sub> at 37° C.

**[0079]** Cells were plated in growth media in 96-well microtiter plates at a 100uL volume. Cells were then incubated for 24 hours at 37°C in a humidified incubator. The test agent (Plinabulin)'s doses were achieved using HP D300 Digital Dispenser. Briefly, the digital dispenser added test agent (Plinabulin) in a DMSO solvent at precise volumes to media containing wells. Control wells received equivolumes of DMSO that test agent (Plinabulin) wells received. Following addition of the test agents, cells were exposed at the concentrations and dilutions described in Table 1 for 72 hours at 37°C in a humidified incubator. Following 72 hour exposure, Plinabulin and control media were removed and 200μl of a 1:1 mixture of media and CellTiter-Glo® Reagent was added to each well. The plates were incubated for 60 minutes at 37°C in a humidified incubator. After incubation, luminescence was recorded using a luminometer.

Table 1: Single Agent Cell Viability Assay

Test Agents Concentrations	1μM high: 10 concentrations; 1:3 dilutions*
Standard Agent Concentrations	1-100μM high <sup>1</sup> : 10 concentrations; 1:3 dilutions <sup>2</sup>
Assay Exposure Time	72 hours continuous
Method	CellTiter-Glo® Cell Viability Assay
Replicates	3 replicates per concentration; 2 technical replicates

<sup>1</sup>Concentrations and dilution factor may be changed after initial screen to optimize curve fitting.

<sup>2</sup>High concentration were selected based on the expected activity of the respective SOC.

**[0080]** Data were expressed as the percent cell growth of the untreated (vehicle) control calculated from the luminescence signals. The surviving fraction of cells was determined by dividing the mean luminescence values of the samples treated with Plinabulin by the mean luminescence values of untreated control. The inhibitory concentration (IC<sub>50</sub>) value for the Plinabulin treated sample and control were estimated

using Prism 6 software (GraphPad Software, Inc.) by curve-fitting the data using the non-linear regression analysis.

Table 2. Summary of Plinabulin IC<sub>50</sub> results for various cancer cell lines with RAS mutant

Cells	RAS mutant	Tissue Type	IC <sub>50</sub> (nM)
KMS-27	NRAS (p.Q61R)	Human Multiple Myeloma	7.84
MOLP-8	NRAS (p.Q61L)	Human Multiple Myeloma	4.22
MM.1S	KRAS(p.G12A)	Human Multiple Myeloma	18.99
L363	NRAS (p.Q61H)	Human Multiple Myeloma	9.44
SNG-M	KRAS(p.G12V)	Human Endometrial	13.08
HEC1a	KRAS(p.G12D)	Human Endometrial	57.74
HCT-15	KRAS(p.G13D)	Human Colorectal	13.08
LoVo	KRAS(p.G13D)	Human Colorectal	6.85
HCT116	KRAS(p.G13D)	Human Colorectal	32.75
RXF-393	KRAS(p.D153V)	Human Renal	4.37
AsPC-1	KRAS(p.G12D)	Human Pancreatic	16.92
Capan-2	KRAS(p.G12V)	Human Pancreatic	10.33
MIA PaCa- 2	KRAS(p.G12C)	Human Pancreatic	92.31

**[0081]** As shown in Table 2, Plinabulin as a single active agent has cytotoxic effects at low IC<sub>50</sub> concentrations on various tumor cell lines with a RAS mutation, including both KRAS and NRAS mutations.

#### Example 2

**[0082]** The combination of Plinabulin and Docetaxel was tested and its activity compared to the standard chemotherapeutic Docetaxel in the A549 (KRAS G12S) human lung tumor xenograft model. The experimental data determined potential additive or synergistic effects of Plinabulin in combination with Docetaxel in the A549 model.

#### A549 Human Lung Tumor Xenograft Model

**[0083]** Female nude mice (nu/nu) between 5 and 6 weeks of age weighing approximately 20g were obtained from Harlan, Inc. (Madison, WI). The A549 human lung tumor cell line was obtained from the American Type Culture Collection (ATCC).

The A549 human lung tumor cell line had mutation at KRAS G12S. The tumor originates from an explant culture of lung carcinomatous tissue from a 58 yr old caucasian male. Animals were implanted subcutaneously (s.c.) by trocar with fragments of A549 human tumor carcinomas harvested from s.c. growing tumors in nude mice hosts. When the tumors were approximately 46mg in size (18 days following inoculation), the animals were pair-matched into treatment and control groups. The negative control group contained 8 tumor mice and all other groups contained 9 tumor mice. Each mouse was ear-tagged and followed individually throughout the experiment. The study was conducted in a non-GLP setting. Initial doses were given on Day 1 following pair matching. Plinabulin at 7.5mg/kg was administered i.p. on two different schedules - Days 1, 4, 8, 11, and 15 and qdx5 (once dose every day for five days). 12.5% dimethylsulfoxide (DMSO), 5% cremophor, and 82.5% peanut oil were combined and administered i.p.; qdx5 to serve as the negative control. Docetaxel (Aventis) was administered i.v. on Days 1, 3, and 5 at 12.5mg/kg was administered i.p.; wklyx3 at 100mg/kg to serve as the positive control. Plinabulin at 7.5mg/kg with the qdx5 schedule was also administered in combination with Docetaxel at the same dose, route, and schedule as the single agent. In the Plinabulin and Docetaxel combination group, Docetaxel was administered 15-30 minutes prior to Plinabulin.

**[0084]** Plinabulin was weighed, and then 12.5% DMSO, 5% cremophor, and 82.5% peanut oil was added, respectively. Finally, the compounds were mixed by vortex and injected within one hour.

**[0085]** Each group contained eight mice. Mice were weighed twice weekly, and tumor measurements were obtained using calipers twice weekly, starting on Day 1. These tumor measurements were converted to mg tumor weight by the standard formula,  $(W_2 \times L)/2$ . The experiment was terminated when the control group tumor size reached an average of 1 gram. Upon termination, the mice were weighed, sacrificed and their tumors were excised. The tumors were weighed, and the mean tumor weight per group was calculated. In this model, the mean treated tumor weight/mean control tumor weight  $\times 100$  was subtracted from 100% to give the tumor growth inhibition (TGI) for each group. One-tailed t-tests using GraphPad Prism<sup>®</sup> Software (Macintosh version 3.0) were used to calculate p-values.

**[0086]** Some agents may have caused tumor shrinkage in this tumor xenograft model. With these agents, the final weight of a given tumor was subtracted from its own

weight at the start of treatment on Day 1. This difference was divided by the initial tumor weight to give the % regression. A mean % tumor regression was calculated from data from mice in a group that experienced tumor regressions.

### **Negative and Positive Controls**

**[0087]** The negative control group had a final mean tumor weight on Day 56 of  $870.4\text{mg} \pm 305.1$ . Docetaxel (12.5 mg/kg; i.v.; Days 1, 3, 5) served as the positive control for the study and had a final mean tumor weight of  $655.1\text{mg} \pm 109.2$  and  $691.4 \pm 175.8$ , respectively. This resulted in a TGI of 26.1% for Docetaxel, compared to the vehicle control group and was within the expected activity range seen in past A549 studies performed. There were no toxic deaths observed in the Docetaxel or Irinotecan groups.

**[0088]** Animals in the Docetaxel group experienced some weight loss. On Day 11, initial mean weight loss was recorded at 2.7%. By Day 22, animals had regained their weight and showed a positive weight gain of 15.4%. There were no toxic deaths observed in the positive control group.

### **Plinabulin and Docetaxel Combination**

**[0089]** Intraperitoneal administration of Plinabulin at 7.5 mg/kg on Days 1-5 resulted in a mean final tumor weight of  $1525.7\text{ mg} \pm 355.3$ . The combination group of Plinabulin (7.5 mg/kg; Days 1-5) and Docetaxel (12.5 mg/kg; i.v.; Days 1,3,5) had a final mean tumor weight on Day 56 of  $265.8\text{ mg} \pm 113.1$ . This resulted in a TGI of 74.3%. The combination was superior to the Docetaxel treatment group, which had a mean final tumor weight of  $655.1\text{mg} \pm 109$ , and the difference between the combination group and the Docetaxel single agent group was statistically significant ( $p < 0.05$ ).

**[0090]** Animals in the Plinabulin single agent group experienced weight gain. On Days 11 and 22, mean weight gain was recorded at 10.6% and 21.8%, respectively. There were no toxic deaths observed in this dose group. Animals in the combination group experienced weight loss. On Day 11, initial mean weight loss was recorded at 2.7%. By Day 22, animals had regained their weight and showed a 16% weight gain.

**[0091]** At the dose levels and schedules evaluated, animals experienced no toxicity with Plinabulin as a single agent. In all five studies, only one death occurred in the Plinabulin group when administered as a single agent. FIG. 3 shows the tumor weight

autopsy in the mice when Plinabulin (7.5 mg/kg) was used in combination with Docetaxel (12.5 mg/kg) through intraperitoneal route. Plinabulin in combination with Docetaxel against the A549 lung tumor model demonstrated a statistically significant ( $p < 0.05$ ) increase in TGI, when compared to Docetaxel alone (74.3% vs. 26.1%). The results indicated strong tumor growth inhibition for the combination of Plinabulin and Docetaxel when compared to Docetaxel as a single agent, showing potential additive or synergistic effects of Plinabulin in combination with Docetaxel in the A549 (KRAS G12S) human lung tumor xenograft model.

### Example 3

**[0092]** The mouse model of glioma used was a PDGF-driven GEMM of glioma that mimics the proneural molecular subgroup of glioblastoma (GBM). This model was based on somatic cell-specific gene transfer; the replication-competent ALV-splice acceptor (RCAS) retroviral system allowed the instillation of particular genetic alterations within tightly regulated windows of differentiation in a cell type-specific manner. The RCAS/*tv-a* system employed the RCAS retroviral vector to infect mice genetically engineered to express the RCAS receptor (*tv-a*) in specific cell populations. Here, gliomas were generated by RCAS-mediated transfer of PDGF to nestin-expressing cells in the brain. Nestin was expressed in a stem/progenitor cell population in the brain, and has been demonstrated to be a marker for cancer stem cells located in perivascular regions (PVN) in both human and mouse brain tumors. PDGF-driven gliomas arose with complete penetrance when combined with *Ink4a-arf-/-* deletion by 4-5 weeks post-infection. These tumors closely mimicked the “proneural” subtype of GBM, in which *CDKN2A* (encoding for both *p16INK4A* and *p14ARF*) deletion was observed in 56% of “proneural” human gliomas. The tumor cell structures that define human gliomas, such as Scherer structures, microvascular proliferation and pseudopalisading necrosis were recreated in this GEMM as shown in FIGS. 1a-1d. Moreover, glioma cells migrated along white matter tracks, surrounded neurons and blood vessels and accumulate at the edge of the brain in the sub-pial space. In this regard, PDGF-driven GEMMs of glioma closely resembles PN-GBM, and represents an excellent experimental system to define the interactions between tumor cells and non-neoplastic cells in the tumor microenvironment.

**[0093]** The PDGF-induced model of glioma were used to determine response to radiation and temozolomide as shown in FIG. 2. Glioma-bearing mice were identified

by symptoms and verified by T2 weighted MRI. These mice were either treated with vehicle, temozolomide at 25 mg/kg daily for 12 days, or fractionated radiation at a dose of 2Gy per day 5 days per week for 2 weeks (20Gy total). The top two images in FIG. 2 shows the growth of tumors that were untreated (vehicle); and in contrast, both the temozolomide treated and irradiated tumors shrank in volume over that same period of time. These tumors recurred after treatment and all animals died of recurrent tumor as can be seen in the survival curves for these corresponding cohorts of mice. The testing data for treatment with radiation and temozolomide illustrated that: 1) trials were performed in this mouse model, 2) the effect of these treatments on mice survival mirrored the human condition, 3) all the mice died of disease, and 4) the relatively homogenous outcomes of these murine cohorts supported the use of this experimental paradigm to detect survival differences in the study.

**[0094]** PDGF-induced model of glioma prepared using the procedures described above were generated. The mice were transgenic for expression of the RCAS receptor (tv-a) from the nestin promoter and having a background of *ink4a/arf-/-* and *lox-stop-lox* luciferase, were infected with RCAS-PDGF and RCAS-KRAS that expressed G12D mutant KRAS. The resultant tumors occurred within the first 3-4 weeks. The tumors had the histological characteristics of GBM and can be identified by symptoms of lethargy and poor grooming, MRI scans using a T2 weighted sequence, or bioluminescence imaging with an IVIS system. Mice in the treatment group (KRAS tumor) were administered i.p. with Plinabulin 7.5mg/kg two times per week for 10 wks, and mice in the control group were administered with Plinabulin diluent (40% wt Kolliphor and 60% wt propylene glycol) only. These treated mice began to gain weight and show improved symptoms within a few days

**[0095]** Plinabulin was tested on Mice with PDGF-induced gliomas that expressed G12D mutant KRAS. 4-6 week old *nestin-tv-a/ink4a-arf-/-* mice were anesthetized with Isoflurane and injected with Df-1 cells transfected RCAS-PDGF-B-HA, RCAS-KRAS. Mice were injected with one microliter of a 1:1 mixture of  $2 \times 10^5$  RCAS-PDGF-B-HA/RCAS-KRAS using a stereotactic frame via a 26-gauge needle attached to a Hamilton syringe. Cells were injected into the right frontal cortex, coordinates bregma 1.75 mm, Lat -0.5mm, and a depth of 2mm. Mice were monitored carefully for weight loss and put on the study when they lost  $> 0.3$  grams total over 2 consecutive days or displayed outward signs of a tumor. The mice were entered into a study group and treated

with either Plinabulin or Plinabulin diluent as described above while consecutively being monitored for lethargy, hunched posture, appetite loss, outward signs of tumor growth, agitation, weight-loss and overall failure to thrive. The mice were sacrificed when they lost more than 20% of their body weight, mobility, inability to feed or weighed less than 14 grams for a male/ 12 grams for a female. The mice were sacrificed using CO<sub>2</sub>; brains were harvested and stored O/N in 10% Neutral buffered formalin and then replaced with Flex 80 and stored at 4 degrees.

**[0096]** FIG. 4 shows the survival rate of mice with Glioblastoma with the G12D Kras mutation. As shown in FIG 4, mice having the PDGF-induced model of Glioblastoma generally had a significantly better survival rate in the Plinabulin treated group as compared to the control group (p=0.001).

#### Example 4

**[0097]** Mice with PDGF-induced gliomas that expressed G12D mutant KRAS were prepared using the procedures according to Example 3 and used in this experiment. 4-6 week old *nestin-tv-a/ink4a-arf-/-* mice were anesthetized with Isoflurane and injected with Df-1 cells transfected RCAS-PDGF-B-HA, RCAS-KRAS. Mice were injected with one microliter of a 1:1 mixture of 2X10<sup>5</sup> RCAS-PDGF-B-HA/RCAS-KRAS using a stereotactic frame via a 26-gauge needle attached to a Hamilton syringe. Cells were injected into the right frontal cortex, coordinates bregma 1.75 mm, Lat -0.5mm, and a depth of 2mm. Mice were monitored carefully for weight loss and put on the study when they lost > 0.3 grams total over 2 consecutive days or displayed outward signs of a tumor.

**[0098]** The mice were entered into two study groups. One group was treated with the combination of temozolomide (TMZ), Radiation and Plinabulin: radiation was given at 10gy x1, TMZ and Plinabulin 7.5 mg/kg in Plinabulin diluent was administered intraperitoneally twice a week on Monday and Thursday for 10 weeks. The other group, the control group, was treated with the combination of TMZ and radiation: radiation was given at 10gy x1, TMZ was administered intraperitoneally twice a week on Monday and Thursday for 10 weeks. the mice were monitored for lethargy, hunched posture, appetite loss, outward signs of tumor growth, agitation, weight-loss and overall failure to thrive. The mice were sacrificed when they lost more than 20% of their body weight, mobility, inability to feed or weighed less than 14 grams for a male/ 12 grams for a female. The mice were sacrificed using CO<sub>2</sub>; brains were harvested and stored O/N in 10% Neutral buffered formalin and then replaced with Flex 80 and stored at 4 degrees. As shown in

FIG. 5, the mice having the PDGF-induced model of Glioblastoma generally had significantly better survival rate in the Plinabulin, TMZ, and radiation treated group as compared to the control group that received TMZ and radiation ( $p=0.0149$ ).

#### Example 5

**[0099]** The combination of Plinabulin and irinotecan was tested and its activity was compared to the standard chemotherapeutic irinotecan in the HCT-15 (KRAS mutation G13D; P53 mutation S241F) human colon tumor xenograft model. The experimental data determined synergistic effects of Plinabulin in combination with irinotecan in the HCT-15 model.

##### HCT-15 Human Colon Tumor Xenograft Model

**[0100]** Female Athymic nude mice (Hsd:Athymic Nude-Foxn1<sup>nu</sup>) were supplied by Harlan (Indianapolis, IN). Mice were received at 4 weeks of age. All mice were acclimated prior to handling. The HCT-15 human colon tumor cell line was received from ATCC (Manassas, VA). Cultures were maintained in RPMI-1640 (Lonza; Walkersville, MD) supplemented with 10% fetal bovine serum (FBS; Seradigm; Radnor, PA), and housed in a 5% CO<sub>2</sub> atmosphere. The cultures were expanded in tissue culture flasks at a 1:10 split ratio until a sufficient amount of cells were harvested. The HCT-15 human colon tumor cell line had mutations at KRAS G13D and P53 S241F.

**[0101]** Female mice were inoculated in the subcutaneous right flank with 0.1 ml of a 50% Media/50% Matrigel mixture containing a suspension of HCT-15 tumor cells ( $5 \times 10^6$  cells/mouse).

**[0102]** Plinabulin (80 mg/20 mL in 40% Solutol:60% propylene glycol) was diluted in a sterile 5% dextrose solution to a concentration of 0.75 mg/mL. Plinabulin at 7.5mg/kg was administered i.p. twice weekly until the end of the study. Plinabulin vehicle (40% soltol:60% propylene glycol) was diluted in sterile 5% dextrose solution in the same ratio as for plinabulin and was used as a negative control. Irinotecan (Teva Pharmaceuticals (Irvine, CA) was diluted in 0.9% sodium chloride solution to a concentration of 10 mg/ml to deliver a dose of 100 mg/kg in a 10 ml/kg dose volume. Irinotecan was dosed intraperitoneally at a dose of 100 mg/kg once weekly for three weeks to serve as a positive control. Plinabulin was also administered in combination with irinotecan at the same dose, route, and schedule as the single agent. In the Plinabulin and irinotecan combination group, irinotecan was administered 120 minutes prior to Plinabulin.

**[0103]** Seven days following inoculation, tumors were measured using a digital caliper. The calipers were used to measure width and length diameters of the tumor. The measured values were digitally recorded using animal study management software, Study Director V.2.1.1 (Study Log). Tumor volumes were calculated utilizing the formula: Tumor volume (mm<sup>3</sup>) = (a x b<sup>2</sup>/2) where 'b' is the smallest diameter and 'a' is the largest diameter<sup>1</sup>. Forty mice with tumor sizes of 104-125 mm<sup>3</sup> were randomized into four groups of ten mice, each with a mean of approximately 112 mm<sup>3</sup>, by random equilibration using Study Director (Day 1). Tumor volumes and body weights were recorded when the mice were randomized and were taken twice weekly thereafter. Clinical observations were made daily.

**[0104]** The experiment was terminated when the control group tumor size reached an average of 1 gram. Upon termination, the mice were weighed, sacrificed and their tumors were excised. The tumors were weighed, and the mean tumor weight per group was calculated as well as a visual assessment of tumor necrosis.

**[0105]** Mean tumor growth inhibition (TGI) was calculated for Day 27 (the final day of the study). All statistical analyses in the xenograft study were performed with Prism GraphPad® v6.00 software. Differences in Day 27 tumor volumes were confirmed using the Analysis of Variance (ANOVA) test.

#### Negative and Positive Controls

**[0106]** The negative control group had a final mean tumor volume on Day 27 of 1701.4 mm<sup>3</sup> ± 178.0. Irinotecan (100 mg/kg; i.p.; Days 1, 8, 15) served as the positive control for the study and had a final mean tumor volume of 1196.2 mm<sup>3</sup> ± 121.7. This resulted in a TGI of 31.8% for irinotecan, compared to the vehicle negative control group. There were no toxic deaths observed in the negative control or positive groups.

**[0107]** Treatment with vehicle negative control, Plinabulin, and irinotecan were well-tolerated. Some mild body weight loss occurred with the vehicle control group and Plinabulin group in the final few days of the study, but body weight loss was not substantial. Clinical observations consisted primarily of tumor necrosis, which is typical for this tumor model. Combination treatment with Plinabulin and irinotecan was fairly well-tolerated with moderate body weight loss observed.

**[0108]** The combination group of Plinabulin (7.5 mg/kg; Days 1-5) and irinotecan (100 mg/kg, days 1,8 and 15) had a final mean tumor volume on Day 27 of

766.8 mm<sup>3</sup> ± 84.2. This resulted in a TGI of 58.8%. The combination was superior to the irinotecan treatment group, which had a mean final tumor volume of 1196.2 mm<sup>3</sup> ± 121.7, and the difference between the combination group and the irinotecan single agent group was statistically significant (p < 0.05).

**[0109]** At the dose levels and schedules evaluated, animals experienced no toxicity with Plinabulin as a single agent. FIG. 6 shows the tumor volume over the course of the study in the mice when Plinabulin (7.5 mg/kg) was used in combination with irinotecan (100 mg/kg) via the intraperitoneal route. Plinabulin in combination with irinotecan against the HCT-15 colon tumor model demonstrated a statistically significant (p < 0.05) increase in TGI, when compared to irinotecan alone (58.8% vs. 31.8%). The results indicated strong tumor growth inhibition for the combination of Plinabulin and irinotecan when compared to irinotecan as a single agent, showing potential additive or synergistic effect of Plinabulin in combination with irinotecan in the HCT-15 (KRAS G13D) human colon tumor xenograft model.

#### Example 6

**[0110]** The combination of Plinabulin and irinotecan was tested and its activity was compared to irinotecan alone in the LoVo (KRAS mutation p.G13D) human colon tumor xenograft model. The experimental data determined potential additive or synergistic effects of Plinabulin in combination with irinotecan in the LoVo model.

**[0111]** LoVo Human Colon Tumor Xenograft Model: Female Athymic nude mice (Hsd:Athymic Nude-Foxn1<sup>nu</sup>) were supplied by Harlan (Indianapolis, IN). Mice were received at 4 weeks of age. All mice were acclimated prior to handling. The LoVo human colon tumor cell line was received from ATCC (Manassas, VA). Cultures were maintained in F12-K (Corning/Cellgro, Manassas, VA) supplemented with 10% fetal bovine serum (FBS; Seradigm; Radnor, PA), and housed in a 5% CO<sub>2</sub> atmosphere. The cultures were expanded in tissue culture flasks at a 1:3 split ratio until a sufficient amount of cells were harvested. The LoVo human colon tumor cell line had mutations at KRAS p.G13D.

**[0112]** Female mice were inoculated in the subcutaneous right flank with 0.1 ml of a 50% Media/50% Matrigel mixture containing a suspension of LoVo tumor cells (1x10<sup>7</sup> cells/mouse).

**[0113]** Plinabulin (80 mg/20 mL in 40% Solutol:60% propylene glycol) was diluted in a sterile 5% dextrose solution to a concentration of 0.75 mg/mL. Plinabulin at

7.5mg/kg was administered i.p. twice weekly until the end of the study. Plinabulin vehicle (40% soltol:60% propylene glycol) was diluted in sterile 5% dextrose solution in the same ratio as for plinabulin and was used as a negative control. Irinotecan (Teva Pharmaceuticals (Irvine, CA) was diluted in 0.9% sodium chloride solution to a concentration of 10 mg/ml to deliver a dose of 100 mg/kg in a 10 ml/kg dose volume. Irinotecan was dosed intraperitoneally at a dose of 80 mg/kg once weekly for three weeks to serve as the positive control. Plinabulin was also administered in combination with irinotecan at the same dose, route, and schedule as each of the single agents. In the Plinabulin and Irinotecan combination group, Irinotecan was administered 120 minutes prior to Plinabulin.

**[0114]** Seven days following inoculation, tumors were measured using a digital caliper. The calipers were used to measure width and length diameters of the tumor. The measured values were digitally recorded using animal study management software, Study Director V.2.1.1 (Study Log). Tumor volumes were calculated utilizing the formula: Tumor volume (mm<sup>3</sup>) = (a x b<sup>2</sup>/2) where 'b' is the smallest diameter and 'a' is the largest diameter<sup>1</sup>. Forty mice with tumor sizes of 104-125 mm<sup>3</sup> were randomized into four groups of ten mice, each with a mean of approximately 112 mm<sup>3</sup>, by random equilibration using Study Director (Day 1). Tumor volumes and body weights were recorded when the mice were randomized and were taken twice weekly thereafter. Clinical observations were made daily.

**[0115]** The vehicle control was sacrificed after reaching a mean tumor volume of equal to or greater than 1500mm<sup>3</sup> on Day 15 as outlined in the protocol. The treatment groups were ended when the irinotecan group reached a mean tumor volume of 774mm<sup>3</sup> due to mice being found dead or moribund sacrificed. At time of necropsy, the tumors were excised and wet weight measurements were recorded as well as a visual assessment of tumor necrosis.

**[0116]** Mean tumor growth inhibition (TGI) was calculated for Day 27. All statistical analyses in the xenograft study were performed with Prism GraphPad® v6.00 software. Differences in Day 27 tumor volumes were confirmed using the Analysis of Variance (ANOVA) test. A one-tailed Student's T-Test with Welch's correction was also used to verify any differences between each group and the vehicle control, and a two-tailed Student's T-Test was used to verify differences between combination groups and their respective single agents.

**[0117]** The Vehicle Control reached a mean tumor volume of 2078.1 mm<sup>3</sup> on Day 15. This group experienced no appreciable mean body weight loss throughout the study. Nine of ten mice experienced slight to moderate tumor necrosis first observed on Day 12. All animals survived to terminal sacrifice.

**[0118]** Treatment with Plinabulin 7.5 mg/kg resulted in a mean tumor volume of 1279.2 mm<sup>3</sup> on Day 15. This group produced a TGI of 41.0% (n=7) on Day 15. A significant decrease in mean tumor volume was observed (p<0.05) when compared to the vehicle control on Day 15 (Student's T-test). This group experienced no mean body weight loss throughout the study. Nine of ten mice experienced slight to severe tumor necrosis first observed on Day 12. Mouse 5 was moribund sacrificed on Day 19 due to clinical observations indicating morbidity from severe tumor necrosis. Mouse 2, 3, 4, 7, and 10 were found dead during the study. Mouse 8 was found dead due to technical error. Three out of ten mice survived to terminal sacrifice.

**[0119]** Treatment with irinotecan 80 mg/kg resulted in a mean tumor volume of 1156.7 mm<sup>3</sup> on Day 15. This group produced a TGI of 47.2% (n=10) when compared to the vehicle control on Day 15. A significant decrease in mean tumor volume was observed (p<0.05) when compared to the vehicle control on Day 15 (Student's T-test). This group experienced moderate body weight loss with a maximum of 7.4% on Day 20, the final day of the study. Eight of ten mice experienced slight to severe tumor necrosis first observed on Day 12. Mouse 3, 4, and 5 were moribund sacrificed on Day 19, 15, and 18 respectively due to clinical observations indicating morbidity from severe tumor necrosis. Mouse 1 and 10 were found dead on Day 17 and 20 respectively. Five out of ten mice survived to terminal sacrifice.

**[0120]** Treatment with Plinabulin 7.5 mg/kg and irinotecan 80 mg/kg resulted in a mean tumor volume of 468.4 mm<sup>3</sup> by Day 15. This group produced a TGI of 82.4% (n=10) when compared to the vehicle control on Day 15. A significant decrease in mean tumor volume was observed (p<0.05) when compared to the vehicle control on Day 15 (Student's T-test) and single agent Plinabulin (Student's T-test). No significant difference in mean tumor volume was observed when compared to single agent irinotecan on Day 15. This group experienced moderate body weight loss with a maximum of 5.8% on Day 20, the final day of the study. Five of ten mice experienced slight to moderate tumor necrosis first observed on Day 15. All ten mice survived to terminal sacrifice. As shown in FIG. 7, the combination of Plinabulin and irinotecan outperformed irinotecan as a

single agent. Due to the loss of mice in the irinotecan alone group, the mean tumor volumes decreased from 1157 mm<sup>3</sup> on Day 15 to 774 mm<sup>3</sup> on Day 20, causing the perceived shift in performance.

**WHAT IS CLAIMED IS:**

1. A method of treating a cancer characterized by expressing a mutant form of a RAS protein, comprising administering Plinabulin to a subject in need thereof.
2. The method of claim 1, wherein the RAS protein is a KRAS, NRAS or HRAS protein.
3. The method of claim 2, wherein the mutant form of the RAS protein is a mutant form of a K-RAS protein.
4. The method of any one of claims 1 to 3, wherein the cancer is selected from colorectal cancer, pancreatic cancer, renal cancer, lung cancer, liver cancer, breast cancer, prostate cancer, gastrointestinal cancer, peritoneal cancer, melanoma, endometrial cancer, ovarian cancer, cervical cancer, uterine carcinoma, bladder cancer, glioblastoma, brain metastases, salivary gland carcinoma, thyroid cancer, brain cancer, lymphoma, myeloma, and head and neck cancer.
5. The method of any one of claims 1 to 4, wherein the cancer is selected from squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, squamous carcinoma of the lung, hepatocellular carcinoma, colon cancer, endometrial carcinoma, and hepatocellular carcinoma.
6. The method of any one of claims 1 to 5, wherein the cancer is selected from colorectal cancer, prostate cancer, breast cancer, lung cancer, endometrial cancer, multiple myeloma, pancreatic, renal cancer, and glioblastoma.
7. The method of claim 6, wherein the cancer is selected from non-small cell lung cancer, pancreatic cancer, and glioblastoma.
8. The method of claim 7, wherein the cancer is non-small cell lung cancer.
9. The method of any one of claims 3 to 8, wherein the KRAS protein comprises mutation at one or more positions selected from codons 12, 13, 59, 61, and 146.
10. The method of any one of claims 3 to 8, wherein the mutant form of the KRAS protein comprises mutation at one or more amino acid positions selected from G12, G13, S17, P34, A59, and Q61.
11. The method of claim 10, wherein the mutant form of the KRAS protein comprises one or more amino acid substitutions selected from the group consisting of G12C, G12S, G12R, G12F, G12L, G12N, G12A, G12D, G12V, G13C, G13S, G13D, G13V, G13P, S17G, P34S, A59E, A59G, A59T, Q61K, Q61L, Q61R, and Q61H.

12. The method of any one of claims 3 to 8, wherein the mutant form of the KRAS protein comprises mutation at one or more amino acid positions selected from G12, G13, A59, Q61, K117 and A146.

13. The method of claim 12, wherein the mutant form of the KRAS protein comprises one or more amino acid substitutions selected from the group consisting of G12C, G12R, G12S, G12A, G12D, G12V, G13C, G13R, G13S, G13A, G13D, G13V, A59E, A59G, A59T, Q61K, Q61L, Q61R, Q61H, K117N, A146P, A146T and A146V.

14. The method of any one of claims 3 to 8, wherein the mutant form of the KRAS protein comprises mutation at one or more amino acid positions selected from of G12, G13 A59, and Q61.

15. The method of claim 14, wherein the mutant form of the KRAS protein comprises one or more amino acid substitutions selected from the group consisting of G12C, G12R, G12S, G12A, G12D, G12V, G13C, G13R, G13S, G13A, G13D, A59E, A59G, A59T, Q61K, Q61L, Q61R and Q61H.

16. The method of any one of claims 3 to 8, wherein the mutant form of the KRAS protein comprises mutation at one or more amino acid positions selected from G12, G13, and D153.

17. The method of claim 16, wherein the mutant form of the KRAS protein comprises one or more amino acid substitutions selected from the group consisting of G12A, G12C, G12D, G12V, G12S, G13D, and D153V.

18. The method of claim 17, wherein the mutant form of the KRAS protein comprises one or more amino acid substitutions selected from G12C, G12S, and D153V.

19. The method of any one of claims 1 to 18, comprising determining whether the subject has a KRAS mutation.

20. The method of claim 2, wherein the mutant form of the RAS protein is a mutant form of a NRAS protein.

21. The method of claim 20, wherein the NRAS protein comprises mutation at one or more positions selected from codons 12, 13, 59, 61, and 146.

22. The method of claim 21, wherein the mutant form of the NRAS protein comprises mutation at Q61 or A146.

23. The method of claim 22, wherein the mutant form of the NRAS protein comprises one or more amino acid substitutions selected from selected from Q61K, Q61H, Q61R, Q61L, Q61N, Q61E, Q61P, A146T, A146P, and A146V.

24. The method of any one of claims 20 to 23, comprising determining whether the subject has a NRAS mutation.
25. The method of any one of claims 20 to 23, comprising determining whether the subject has a HRAS mutation.
26. The method of any one of claims 1 to 25, comprising co-administering Plinabulin with an additional active agent.
27. The method of claim 26, wherein the additional active agent is an additional therapeutic agent.
28. The method of claim 27, wherein the additional therapeutic agent is Docetaxel and the cancer is human non-small cell lung cancer.
29. The method of claim 27, wherein the additional therapeutic agent is Irinotecan and the cancer is human colon cancer.
30. A method of inhibiting proliferation of a cell having a RAS mutation, comprising contacting the cell with Plinabulin.
31. The method of Claim 30, wherein the contacting comprises administering Plinabulin to a subject having the cell.
32. A method of inducing apoptosis in a cell having a RAS mutation, comprising contacting the cell with Plinabulin
33. The method of Claim 32, wherein the contacting comprises administering Plinabulin to a subject in need thereof.
34. A method of inhibiting progression of a cancer characterized by expressing a mutant form of a RAS protein in a subject, comprising administering Plinabulin to a subject in need thereof.




FIG. I




FIG. 2




FIG. 3

4/6




FIG. 4






FIG. 5



6/6



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2016/020390

## A. CLASSIFICATION OF SUBJECT MATTER

**A61K 31/496 (2006.01) A61P 35/00 (2006.01)**

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Databases: WPIAP, EPODOC, MEDLINE, CAPLUS, EMBASE, BIOSIS, Esp@cenet, PubMed and Internal databases provided by IP Australia

Keywords: Plinabulin, NPI-2358, UNII-986FY7F8XR, 714272-27-2, phenylahistin, cancer, tumour, neoplasm, malignant, metastases, melanoma, carcinoma, adenocarcinoma, glioblastoma, lymphoma, myeloma, proliferation, apoptosis, RAS, and similar terms, as well as the Applicants/Inventors names.

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	Documents are listed in the continuation of Box C	

 Further documents are listed in the continuation of Box C See patent family annex

* Special categories of cited documents:		
"A" document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search  
19 May 2016Date of mailing of the international search report  
19 May 2016

## Name and mailing address of the ISA/AU

AUSTRALIAN PATENT OFFICE  
PO BOX 200, WODEN ACT 2606, AUSTRALIA  
Email address: pct@ipaaustralia.gov.au

## Authorised officer

Christina van Broekhoven  
AUSTRALIAN PATENT OFFICE  
(ISO 9001 Quality Certified Service)  
Telephone No. 0262833196

INTERNATIONAL SEARCH REPORT		International application No.
C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		PCT/US2016/020390
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Heist, R. et al. 2014 "Randomized phase 2 trial of plinabulin (NPI-2358) plus docetaxel in patients with advanced non-small cell lung cancer (NSCLC)." J. Clin. Oncol. Vol.32, No. 5s, (suppl; abstr 8054) see Abstract and Background	1-34
Y	Singh, A. et al. 2011 "A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells." Blood. Vol. 117, No. 21, pp. 5692-5700 see pp. 5698-9	1-34
Y	Wang, T. et al. 1998 "Microtubule interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways". J Biol Chem. Vol. 273, No. 9, pp. 4928-4936 see pp. 4928 and 4935	1-34
Y	Prior, I. et al. 2012 "A Comprehensive Survey of Ras Mutations in Cancer" Cancer Res. Vol. 72, no. 10, pp.2457-2467 see Figure 1 and Table 2	1-34
Y	Mita, M. et al. 2010 "Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas". Clin. Cancer. Res. Vol. 16, no. 23, pp. 5892-5899 see pp. 5897-8	26-29
A	WO 2005/077940 A1 (NEREUS PHARMACEUTICALS, INC.) 25 August 2005 see whole document	1-34
P,A	WO 2015/051543 A1 (BEYONDSPRING PHARMACEUTICALS, INC.) 16 April 2015 see whole document	1-34

<b>INTERNATIONAL SEARCH REPORT</b> Information on patent family members		International application No. <b>PCT/US2016/020390</b>	
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.			
Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
WO 2005/077940 A1	25 August 2005	WO 2005077940 A1	25 Aug 2005
		AU 2003302721 A1	09 Jul 2004
		AU 2003302721 B2	08 Oct 2009
		AU 2005212399 A1	25 Aug 2005
		AU 2005212399 B2	22 Sep 2011
		BR 0313363 A	09 Aug 2005
		BR PI0506655 A	08 May 2007
		CA 2494049 A1	01 Jul 2004
		CA 2553630 A1	25 Aug 2005
		CN 1684955 A	19 Oct 2005
		CN 1934101 A	21 Mar 2007
		CN 1934101 B	12 Oct 2011
		CN 101633655 A	27 Jan 2010
		CN 101633655 B	30 Apr 2014
		CO 5721010 A2	31 Jan 2007
		EP 1529044 A2	11 May 2005
		EP 1529044 B1	03 Oct 2007
		EP 1711487 A1	18 Oct 2006
		EP 1926724 A1	04 Jun 2008
		HK 1078080 A1	01 Feb 2008
		HK 1084388 A1	24 Dec 2009
		IL 166628 A	30 Aug 2012
		JP 2006511534 A	06 Apr 2006
		JP 4616649 B2	19 Jan 2011
		JP 2007520565 A	26 Jul 2007
		KR 20050083610 A	26 Aug 2005
		KR 101049100 B1	15 Jul 2011

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.

Form PCT/ISA/210 (Family Annex)(July 2009)

<b>INTERNATIONAL SEARCH REPORT</b> Information on patent family members		International application No. <b>PCT/US2016/020390</b>
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.		
Patent Document/s Cited in Search Report		Patent Family Member/s
Publication Number	Publication Date	Publication Number
		KR 20110039500 A
		KR 101184374 B1
		KR 20060124743 A
		KR 101228104 B1
		MX PA05001217 A
		NZ 538433 A
		NZ 548659 A
		US 2005090667 A1
		US 7064201 B2
		US 2006217553 A1
		US 7674903 B2
		US 2007078138 A1
		US 7919497 B2
		US 2005197344 A1
		US 7935704 B2
		US 2006223823 A1
		US 7956058 B2
		US 2011245260 A1
		US 8247552 B2
		US 2012277251 A1
		US 8618292 B2
		US 2006223822 A1
		WO 2004054498 A2
		WO 2007035841 A1
		ZA 200501616 A
		ZA 200607151 A
WO 2015/051543 A1	16 April 2015	WO 2015051543 A1
		CA 2926771 A1
<b>End of Annex</b>		
Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001. Form PCT/ISA/210 (Family Annex)(July 2009)		

## 摘要

本文公開了治療癌症的方法，其特徵在於表達突變形式的RAS蛋白。一些實施方案涉及通過將Plinabulin施用於需要其的受試者來治療癌症。